2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer group
2014
Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice
Tan W, Lamb B, Payne H, Hughes S, Green J, Lane T, Adshead J, Boustead G, Vasdev N. Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer 2014, 13: e153-e158. PMID: 25510376, DOI: 10.1016/j.clgc.2014.11.006.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapy regimenNeoadjuvant chemotherapyPositive lymph nodesRadical cystectomyAdjuvant chemotherapyTreatment of patientsBladder cancerNodal diseaseLymph nodesIndication of adjuvant chemotherapyNode-positive bladder cancerPresence of disease progressionResponse to NACCancer CenterMuscle-invasive bladder cancerCycles of gemcitabineAdvanced bladder cancerPatient performance statusUro-oncologistsChemotherapy regimenPerformance statusLack of published evidenceDisease progressionChemotherapyPatients